AZNAstraZenecaRunning, no new patients
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 358 (final count)
- Started
- Dec 16, 2020
- Main results expected
- Oct 15, 2024
- Fully finished
- Jun 13, 2029
- Results posted
- Jun 5, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Major Pathological Response (MPR) - IASLC Method
Measured over: From date of randomization to an average of 12 weeks after the first dose
Major Pathological Response (MPR) - Chemotherapy Method
Measured over: From date of randomization to an average of 12 weeks after the first dose
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04351555 · record last updated 2026-09-09 · checked 2026-11-09 15:47 UTC